EUVIMEDEUVIMED entdecken
Open Access

Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction

Esraa Eloseily iD, Alex Pickering, Sanjeev Dhakal, Nicolino Ruperto iD, Hermine I Brunner iD, Alexei A Grom, Sherry Thornton, Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation

Arthritis Care & Research · 2025

DOI: 10.1002/acr.25459 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, 2025. Verfasst von Esraa Eloseily und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Southwestern Medical Center, Dallas, and Assiut University Faculty of Medicine, Assiut, Egypt. Hauptthemen laut MEDLINE: Arthritis, Juvenile, Piperidines, Pyrimidines, Gene Expression Profiling. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, Systemic JIA foundation, Cincinnati Children's Hospital Medical Center Pediatric Musculoskeletal & Rheumatology Innovation Core center (PORTICO).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess changes in gene expression following tofacitinib treatment and investigate transcription patterns as potential predictors of treatment response in patients with active juvenile idiopathic arthritis (JIA).

Methods

Whole‐blood samples were collected from patients with JIA at baseline and after 18 weeks of open‐label tofacitinib treatment. Patients who achieved a JIA–American College of Rheumatology (ACR) response of 70% or above at week 18 were classified as treatment responders (TRs), whereas those with at most a JIA–ACR30 were classified as poor responders (PRs). Differential gene expression and gene ontology overrepresentation analyses were performed to compare RNA expression between week 18 and baseline samples, as well as between PR and TR samples at baseline.

Results

Samples from 67 patients at baseline and 60 patients at week 18 were analyzed. After 18 weeks of tofacitinib treatment across all patients with JIA, 883 genes showed significant differential expression (week 18 to baseline). The most strongly down‐regulated genes were overrepresented within interleukin‐7 (IL‐7) and type I and type II interferon pathways, whereas up‐regulated genes were enriched in ontologies related to neuronal cell processes and cell signaling. Comparing PRs and TRs at baseline, 663 genes showed differential expression. Up‐regulated genes were overrepresented within ontologies including activation of MAPK activity ( P = 9.40 × 10 −5 ), myeloid cell development ( P = 8.13 × 10 −5 ), activation of GTPase activity ( P = 0.00015), and organelle transport along microtubules ( P = 0.00021).

Conclusion

Tofacitinib treatment in JIA down‐regulated genes in interferon and IL‐7 signaling pathways regardless of effectiveness. Furthermore, baseline up‐regulation of MAPK signaling may predict poor response to tofacitinib treatment in JIA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, JuvenilePiperidinesPyrimidinesGene Expression ProfilingPyrrolesProtein Kinase InhibitorsTranscriptomeHumansChildMaleFemaleTreatment OutcomeAdolescentChild, PreschoolJanus Kinase Inhibitors

Substanzen

tofacitinibPiperidinesPyrimidinesPyrrolesProtein Kinase InhibitorsJanus Kinase Inhibitors

Autor:innen und Institutionen

  • University of Texas Southwestern Medical Center, Dallas, and Assiut University Faculty of Medicine, Assiut, Egypt.
  • Harvard Medical School, Cambridge, Massachusetts.
  • Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Università Milano Bicocca and IRCCS Fondazione San Gerardo dei Tintori/Paediatric Rheumatology International Trials Organisation, Monza, Italy.

ORCID-Profile: Esraa Eloseily, Nicolino Ruperto, Hermine I Brunner

Förderung

  • NIAMS NIH HHS
  • Systemic JIA foundation
  • Cincinnati Children's Hospital Medical Center Pediatric Musculoskeletal & Rheumatology Innovation Core center (PORTICO)
  • Dr. Ralph and Marian Falk Medical Research Trust
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Eloseily, E., Pickering, A., Dhakal, S., Ruperto, N., Brunner, H. I., Grom, A. A., Thornton, S., & Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation (2025). Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction. Arthritis Care & Research. https://doi.org/10.1002/acr.25459

Vancouver

Eloseily E, Pickering A, Dhakal S, Ruperto N, Brunner HI, Grom AA, et al. Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction. Arthritis Care & Research. 2025. doi:10.1002/acr.25459

BibTeX
@article{Eloseily2025,
  author = {Eloseily, Esraa and Pickering, Alex and Dhakal, Sanjeev and Ruperto, Nicolino and Brunner, Hermine I and Grom, Alexei A and Thornton, Sherry and Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation, Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation},
  title = {Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction},
  journal = {Arthritis Care & Research},
  year = {2025},
  doi = {10.1002/acr.25459}
}
Kostenlos starten →